🔍

LAURUSLABS - Laurus Labs

📊 NSE: LAURUSLABS 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 9:12

📢 Recent Corporate Announcements

Laurus Labs Recommends S.R. Batliboi & Associates as Statutory Auditors for 5-Year Term

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 12 Mar 2026, 06:42 PM

Laurus Labs has recommended the appointment of S.R. Batliboi & Associates LLP as its new Statutory Auditors for a five-year term starting from the 2027 AGM. This change is a routine regulatory requirement as the current auditors, Deloitte Haskins & Sells LLP, will complete their mandatory second term in 2027. The appointment will span from the conclusion of the 22nd AGM in 2027 until the 27th AGM in 2032. The transition is subject to shareholder approval at the upcoming 2027 Annual General Meeting.

S.R. Batliboi & Associates LLP recommended for a 5-year term from 2027 to 2032
Current auditors Deloitte Haskins & Sells LLP to exit after completing their second term in 2027
Appointment is subject to shareholder approval at the 22nd Annual General Meeting
New auditors have extensive experience in the pharmaceutical and industrial sectors
The Board meeting for this recommendation concluded on March 12, 2026

💡 This is a routine auditor rotation required under the Companies Act; investors should view this as standard corporate governance and no immediate action is required.

Laurus Labs to Host Facility Visit and Management Interaction on March 18, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Mar 2026, 03:13 PM

Laurus Labs Limited has scheduled an in-person interaction with a group of analysts and institutional investors on March 18, 2026. The meeting will take place in Visakhapatnam and will include a facility visit alongside management discussions. This event is part of the company's regular investor engagement program under SEBI Regulation 30. The company has explicitly stated that no unpublished price sensitive information will be shared during this interaction.

In-person meeting and facility visit scheduled for March 18, 2026, in Visakhapatnam
Interaction involves a group of analysts and institutional investors
Compliance filing pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015
Company confirms no Unpublished Price Sensitive Information (UPSI) will be disclosed

💡 Investors should monitor for any subsequent research reports or notes from participating brokerages that may provide qualitative insights into the company's operational state. No immediate trading action is required based on this routine disclosure.

Laurus Labs to Participate in Investec India Conference 2026 on March 12-13

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Mar 2026, 03:20 PM

Laurus Labs Limited has announced its participation in the Investec India Conference 2026. The event is scheduled for March 12-13, 2026, and will be held in Hyderabad. The interaction will consist of in-person group meetings with various analysts and institutional investors. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during these sessions.

Participation in the Investec India Conference 2026 in Hyderabad
Scheduled dates for investor interaction are March 12 and March 13, 2026
Format includes in-person group meetings with institutional investors
Compliance disclosure under Regulation 30 of SEBI LODR Regulations

💡 This is a routine investor relations event; investors should look for any post-conference reports from participating brokerages for insights into management's outlook. No immediate portfolio action is required based on this scheduling update.

Laurus Labs Receives NCLT Approval for Subsidiary Restructuring and Amalgamation

🟢 POSITIVE ⭐ 7/10

M&A 📅 24 Feb 2026, 08:37 PM

Laurus Labs has received approval from the NCLT Amravati Bench for its Composite Scheme of Arrangement involving two wholly-owned subsidiaries. The plan involves demerging Unit-1 of Laurus Synthesis Private Limited (LSPL) into Sriam Labs and merging the remaining LSPL business directly into Laurus Labs Limited. The NCLT has dispensed with meetings for shareholders and creditors of the parent company, significantly streamlining the regulatory path. Meetings for unsecured creditors of the subsidiaries are now scheduled for April 06, 2026, to move the process toward final completion.

NCLT Amravati Bench allowed the First Motion Application for the scheme on February 24, 2026
Unit-1 of Laurus Synthesis Private Limited to be demerged and merged into Sriam Labs Private Limited
Remaining business undertakings of LSPL to be amalgamated with the parent company, Laurus Labs Limited
Meetings of Equity Shareholders and all Creditors of the parent company (Laurus Labs) have been dispensed with
Meetings for Unsecured Creditors of LSPL and Sriam Labs are directed to be held on April 06, 2026

💡 Investors should view this as a positive step toward corporate simplification and operational efficiency. Monitor the outcome of the unsecured creditor meetings in April as the final steps toward full integration of the CDMO business.

Laurus Labs Receives Independent ESG Score of 68.6 for FY 2025

🟡 NEUTRAL ⭐ 4/10

OTHER 📅 20 Feb 2026, 06:54 PM

Laurus Labs has been assigned an Environmental, Social, and Governance (ESG) score of 68.6 out of 100 by SES ESG Research Private Limited for the 2025 financial year. This assessment was conducted independently by the research firm using data available in the public domain, rather than being commissioned by the company. The disclosure is in compliance with SEBI's updated regulatory framework for ESG reporting. Such scores are becoming increasingly critical for institutional investors who prioritize sustainable and responsible investment mandates.

Assigned an independent ESG score of 68.6 out of 100 for FY 2025.
Assessment conducted by SES ESG Research Private Limited without company engagement.
Report based entirely on publicly available data and disclosures.
Complies with SEBI Master Circular requirements dated January 30, 2026.

💡 Investors should view this as a transparency measure; while the score is respectable, it should be benchmarked against pharmaceutical industry peers to assess relative ESG performance.

Laurus Labs to Participate in 17th Annual Kotak Investor Conference on February 24, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 17 Feb 2026, 12:47 PM

Laurus Labs Limited has announced its participation in the 17th Annual Kotak Investor Conference scheduled for February 24, 2026. The event will take place in Mumbai and involve in-person group meetings with various analysts and institutional investors. The company has clarified that no unpublished price sensitive information (UPSI) will be disclosed during these sessions. This is a standard regulatory filing under Regulation 30 of SEBI (LODR) Regulations, 2015.

Participation in the 17th Annual Kotak Investor Conference in Mumbai
Scheduled date for the interaction is February 24, 2026
Interaction format is designated as in-person group meetings
Company confirmed that no unpublished price sensitive information will be shared
Disclosure made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015

💡 No immediate action is required as this is a routine investor relations update. Investors may look for any subsequent investor presentations or transcripts released after the conference for insights into management's outlook.

Laurus Labs Q3 FY26 Revenue Up 26% to ₹1,778 Cr; EBITDA Margins Expand to 27%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 28 Jan 2026, 06:56 PM

Laurus Labs reported a strong Q3 FY26 with revenue growing 26% YoY to ₹1,778 crores, driven by a 37% surge in the generics division. Profitability showed significant improvement as EBITDA margins expanded to 27% and PAT for the 9-month period jumped 388% to ₹610 crores. The company is aggressively investing in high-growth areas like peptides and ADCs, with a planned CAPEX of ₹1,000 crores for both FY26 and FY27. Management maintains a healthy balance sheet with a net debt-to-EBITDA ratio of 1.2x.

Q3 FY26 Revenue grew 26% YoY to ₹1,778 crores with Gross Margins expanding to 60.9%
Generics division revenue rose 37% to ₹1,327 crores, fueled by ARV volumes and new launches
CDMO segment recorded over 50% growth in the 9-month period, despite a phased Q3 performance of ₹408 crores
Planned CAPEX of ₹1,000 crores for FY26 and FY27 to scale peptide and ADC capabilities
9-month PAT surged 388% YoY to ₹610 crores, with ROCE improving to 18.5%

💡 Investors should view the margin expansion and strong CDMO growth as positive indicators of a structural shift in the business mix. Monitor the execution of the new fermentation and ADC facilities for long-term value creation.

Laurus Labs Releases Audio Recording of Q3 FY26 Earnings Conference Call

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 23 Jan 2026, 07:48 PM

Laurus Labs has officially released the audio recording of its Q3 FY26 earnings conference call held on January 23, 2026. This filing follows the company's quarterly financial results announcement and is a standard regulatory requirement under SEBI LODR Regulations. The recording provides investors with direct access to management's commentary regarding the company's performance during the third quarter. Accessing such recordings is crucial for understanding the qualitative aspects of the financial results and future growth guidance.

Audio recording of the Q3 FY26 results conference call is now available for public access.
The conference call was conducted on January 23, 2026, following the quarterly earnings release.
Compliance maintained with Regulation 30 and 46 of SEBI (Listing Obligations and Disclosure Requirements).
The recording contains management's detailed discussion on business operations and financial metrics.

💡 Investors should listen to the recording to understand management's perspective on margin trends and the outlook for the API and CDMO segments. This information is vital for assessing the long-term growth trajectory beyond the reported numbers.

Laurus Labs Q3 Net Profit Surges 174% YoY to ₹252 Cr; EBITDA Margins Expand to 27.3%

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 23 Jan 2026, 02:59 PM

Laurus Labs reported a robust Q3 FY26 with revenue growing 26% YoY to ₹1,778 crore, driven by a 37% surge in the Generics division. Profitability saw a massive jump, with Net Profit increasing 174% to ₹252 crore and EBITDA margins expanding by 720 bps to 27.3%. For the 9M FY26 period, the company crossed the ₹5,000 crore revenue mark with a 104% growth in EBITDA. While the CDMO segment showed 43% growth in the 9M period, the Bio segment faced temporary scale-up challenges with a 9% decline.

Q3 FY26 Net Profit grew 174% YoY to ₹252 Cr, while 9M FY26 Net Profit surged 388% to ₹610 Cr
EBITDA margins improved significantly to 27.3% in Q3, up from 20.1% in the previous year
9M FY26 Revenues reached ₹5,001 Cr (+30% YoY), supported by strong performance in CDMO and Generics
Net Debt leverage improved to 1.2x EBITDA despite ongoing CAPEX at 15% of sales
Generics division revenue grew 37% in Q3, led by higher ARV volumes and developed market offtake

💡 Investors should focus on the significant margin expansion and debt reduction as signs of high operational efficiency. The strong 9M performance and the company's strategic shift toward high-value CDMO projects and Peptides/ADC platforms provide a positive long-term outlook.

Laurus Labs Q3 FY26 Net Profit Surges 174% to ₹252 Cr; 9M Revenue Hits ₹5,001 Cr

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 23 Jan 2026, 02:54 PM

Laurus Labs reported a robust performance for 9M FY26, with revenues growing 30% YoY to ₹5,001 crore and net profit jumping 388% to ₹610 crore. The growth was primarily driven by the CDMO division, which saw 43% growth in the nine-month period, and strong execution in the Generics segment. EBITDA margins expanded significantly to 26.1% for 9M FY26, up from 16.6% in the previous year, aided by a better product mix and operational leverage. The company continues its aggressive CAPEX plan, investing ₹735 crore in 9M FY26 towards new technologies like peptides and gene therapy.

9M FY26 Revenue grew 30% YoY to ₹5,001 Cr, while Net Profit skyrocketed 388% to ₹610 Cr.
EBITDA margins improved by 950 bps to 26.1% in 9M FY26 due to better product mix and scale.
CDMO Small Molecules segment grew 50% in 9M FY26, despite a muted Q3 due to campaign timing.
Net Debt-to-EBITDA significantly reduced to 1.2x from 3.1x a year ago, showing improved financial health.
Cumulative CAPEX for FY22-26 is projected at ~₹3,900 Cr, focusing on high-growth areas like Peptides and ADCs.

💡 Investors should take note of the significant margin expansion and the sharp reduction in leverage, which indicate a strong operational turnaround. The company's transition towards high-value CDMO projects and new modalities like gene therapy provides a positive long-term outlook.

Laurus Labs Q3 FY26 Net Profit Surges 172% YoY to ₹251.66 Cr; Revenue Up 25.7%

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 23 Jan 2026, 02:51 PM

Laurus Labs reported a robust performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 25.7% YoY to ₹1,778.29 crore. Net profit for the quarter witnessed a massive jump of 172.6% YoY, reaching ₹251.66 crore compared to ₹92.30 crore in the same period last year. The nine-month profit for FY26 also showed significant improvement, rising to ₹609.65 crore from ₹124.65 crore YoY. During the quarter, the company also completed strategic investments in Laurus Bio (₹35 crore) and a joint venture with KRKA Pharma (₹49 crore).

Consolidated Revenue from operations increased by 25.7% YoY to ₹1,778.29 crore in Q3 FY26.
Net Profit after tax surged by 172.6% YoY to ₹251.66 crore for the quarter.
Basic Earnings Per Share (EPS) improved significantly to ₹4.67 from ₹1.71 in the previous year's quarter.
Company invested ₹49 crore for a 49% stake in KRKA Pharma Private Limited joint venture during the quarter.
Nine-month total income reached ₹5,044.48 crore, a substantial increase from ₹3,850.19 crore in the prior year period.

💡 The strong recovery in both top-line and bottom-line figures suggests a significant turnaround in operational efficiency and market demand. Investors should maintain a positive outlook while monitoring the progress of the pending NCLT approval for the internal demerger and merger scheme.

Laurus Labs Grants 4.23 Lakh Stock Options to Employees at Rs 754.50 Exercise Price

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 23 Jan 2026, 11:12 AM

Laurus Labs has approved the grant of 4,23,125 stock options to over 1,190 eligible employees under its 2016, 2018, and 2021 ESOP schemes. The exercise price is fixed at Rs 754.50, which represents a 25% discount to the market price as of January 22, 2026. Vesting for these options will occur in multiple stages beginning July 2027 and concluding by July 2030. This initiative is designed to incentivize employees and align their interests with the company's long-term growth objectives.

Total grant of 4,23,125 stock options across three different ESOP schemes (2016, 2018, and 2021).
Exercise price set at Rs 754.50 per share, reflecting a 25% discount to the market price.
Vesting periods span from 2 to 5 years, with the first tranche vesting in July 2027.
A total of 1,194 employees across the company and its subsidiaries are eligible beneficiaries.
Each option converts into one equity share of Rs 2 face value upon exercise within one year of vesting.

💡 This is a routine corporate action for employee retention and should be viewed as neutral for the stock price. Investors should monitor the cumulative dilution from various ESOP schemes over the long term.

Laurus Labs Schedules Q3 & 9M FY26 Earnings Conference Call for January 23, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Jan 2026, 10:35 AM

Laurus Labs has announced its Q3 and 9M FY26 earnings conference call scheduled for January 23, 2026, at 5:00 PM IST. The call, hosted by DAM Capital Advisors, will review the company's financial performance and provide a Q&A session for analysts and investors. Laurus Labs, which reported FY2025 revenue of ₹5,554 crore, continues to leverage its 15 manufacturing sites and 1,250+ scientists. This routine announcement sets the stage for the upcoming quarterly financial disclosure.

Conference call for Q3 & 9M FY26 results set for January 23, 2026, at 17:00 IST.
DAM Capital Advisors to host the interactive session with management.
Company highlights FY2025 annual revenue of ₹5,554 crore.
Infrastructure includes 15 global agency-approved sites and a workforce of 7,000+ employees.

💡 Investors should attend the call to understand the management's outlook on the CDMO business and API pricing trends. No immediate action is required until the actual financial results are released.

Laurus Labs Submits SEBI Regulation 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jan 2026, 09:59 AM

Laurus Labs Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the period ended December 31, 2025. The certificate, issued by KFin Technologies Limited, confirms that all securities dematerialized or rematerialized during the quarter have been properly accounted for and reported to the stock exchanges. This is a standard administrative filing required to ensure the integrity of shareholding records between the company and depositories like NSDL and CDSL. There are no financial or operational changes reported in this disclosure.

Compliance certificate submitted for the quarter ended December 31, 2025.
Issued by Registrar and Share Transfer Agent (RTA), KFin Technologies Limited.
Confirms adherence to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Covers processing of dematerialization and rematerialization requests for both NSDL and CDSL.

💡 This is a routine regulatory filing with no impact on the company's fundamentals or stock price. No action is required from investors.

Laurus Labs to Close Trading Window from Jan 1, 2026, for Q3 FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 29 Dec 2025, 05:51 PM

Laurus Labs Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI insider trading regulations. This closure is ahead of the declaration of the company's un-audited standalone and consolidated financial results for the quarter and nine-month period ending December 31, 2025. The window will remain shut for all designated persons and their relatives until 48 hours after the results are made public. The specific date for the board meeting to approve these results will be communicated at a later date.

Trading window closure effective from January 1, 2026
Closure pertains to financial results for the quarter and nine months ending December 31, 2025
Window to reopen 48 hours after the declaration of financial results
Applies to all Designated Persons, Immediate Relatives, and Connected Persons under the Code

💡 This is a routine regulatory announcement with no direct impact on stock fundamentals. Investors should wait for the upcoming board meeting announcement to track the company's Q3 financial performance.

View All LAURUSLABS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated Gross Income grew 10.17% to INR 5,554 Cr in FY25 from INR 5,041 Cr in FY24. The CDMO segment is expected to scale up significantly in FY26 to drive future growth, following a 16.5% decline in FY24 total operating income (INR 5,044 Cr vs INR 6,041 Cr in FY23) due to lower contract manufacturing contributions.

Geographic Revenue Split

Europe is a primary market contributing 36% of total revenue and 62% of export revenue. The US market contributes less than 10% of total revenue, which limits the company's exposure to USFDA regulatory volatility.

Profitability Margins

Gross margins have expanded from historical levels of 50% to approximately 60% in Q2 FY26 due to a shift toward commercial-stage CDMO programs and leadership in ARV/Oncology. Net Profit After Tax (PAT) surged 122% to INR 358 Cr in FY25 from INR 161 Cr in FY24.

EBITDA Margin

EBITDA margin stood at 20.1% in FY25 (INR 1,115 Cr), a significant improvement from 15.8% in FY24. In Q2 FY26, EBITDA margins expanded by 11 percentage points YoY to reach 26% driven by better asset utilization and product mix.

Capital Expenditure

Laurus Labs has planned a capital expenditure of approximately INR 1,500 Cr over the next two years (FY26-FY27) to support specialized modalities like gene therapy, ADC, and fermentation.

Credit Rating & Borrowing

The company holds a 'CARE AA; Stable' rating for long-term facilities (reaffirmed in July 2025) and 'CARE A1+' for short-term facilities. Interest coverage improved to 4.90x in FY25 from 4.28x in FY24.

⚙️ Operational Drivers

Raw Materials

Key raw materials include chemical intermediates for Active Pharmaceutical Ingredients (APIs) in Anti-Retroviral (ARV), Oncology, Cardiovascular, and Gastro therapeutics. Specific inputs include bio-enzyme catalysts and fermentation-based ingredients.

Import Sources

Not explicitly disclosed in available documents, though the company utilizes natural hedging by netting off imports and exports to mitigate currency risk.

Capacity Expansion

The company operates 15 facilities (including 12 manufacturing sites: 8 in Vizag, 2 in Hyderabad, 2 in Bangalore). New capacity for Laurus Bio is expected to come online by the end of 2026 to support revenue ramp-up in FY27.

Raw Material Costs

Raw material costs are managed through a focus on backward integration and green chemistry platforms like continuous flow chemistry to improve yield and reduce waste.

Manufacturing Efficiency

Efficiency is driven by high asset utilization and a shift from clinical-phase drug development to commercial manufacturing in the CDMO segment.

📈 Strategic Growth

Expected Growth Rate

20%

Growth Strategy

Growth will be achieved through the scale-up of the CDMO segment in FY26, a Joint Venture with KRKA Pharma for new markets, and investments in an ADC (Antibody Drug Conjugate) technology platform. The company is also expanding into specialized modalities like gene therapy and fermentation.

Products & Services

Active Pharmaceutical Ingredients (APIs) for ARV, Oncology, and Cardiovascular treatments; Finished Dosage Forms (FDF); CDMO services for global innovators; and Bio-ingredients.

Brand Portfolio

Laurus Labs, Laurus Bio, Laurus Synthesis, Laurus Generics.

New Products/Services

New ADC integrated services and gene therapy manufacturing are expected to contribute to revenue as capacities come online by end of 2026.

Market Expansion

Expansion is targeted through the KRKA JV and increasing the pipeline of commercial CDMO programs.

Market Share & Ranking

Laurus holds a global leadership position in select APIs, including anti-retrovirals and oncology drugs.

Strategic Alliances

Joint Venture with KRKA Pharma Private Limited; 26% stake in Kurnool Renewables for green energy; investment in an ADC technology platform company.

🌍 External Factors

Industry Trends

The CDMO industry is shifting toward early-stage involvement requiring large upfront CAPEX. Laurus is positioning itself by investing in specialized modalities like ADCs and cell/gene therapy to capture this 15-20% industry growth trend.

Competitive Landscape

Competes with other large CDMO and API players like Divi's Labs. Competition is based on manufacturing scale, regulatory track record, and technical capabilities in complex chemistry.

Competitive Moat

Moat is built on cost leadership in ARV APIs, deep backward integration, and a large R&D talent pool (2,600+ scientists). This is sustainable due to high entry barriers in complex API manufacturing.

Macro Economic Sensitivity

Sensitive to global healthcare spending and pharmaceutical outsourcing trends, particularly in the CDMO sector.

Consumer Behavior

Demand for ARV drugs remains stable; however, a shift toward preventive drugs (PrEP) is monitored, though not expected to have a material impact in the near term.

Geopolitical Risks

Exposure to diverse geographies requires compliance with evolving international regulations; non-compliance can lead to product recalls or reputational damage.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by USFDA, WHO Geneva, ANVISA Brazil, and EMA standards. 7 of 12 sites are USFDA approved. Compliance is critical as non-compliance can lead to import alerts.

Environmental Compliance

Invested in green chemistry and renewable energy (26% stake in Kurnool Renewables). ESG scores improved significantly (S&P score from 59 to 73).

Taxation Policy Impact

The consolidated tax rate is approximately 28%. The parent company has converted to a new tax regime, while subsidiaries operate under different rates.

Legal Contingencies

The company maintains internal financial controls and conducts regular audits to ensure compliance with the Companies Act 2013 and other statutory requirements. Specific pending litigation values are not disclosed.

⚠️ Risk Analysis

Key Uncertainties

Execution risk of large-scale CAPEX (INR 1,500 Cr) and the timing of CDMO order inflows are key uncertainties that could impact profitability by 5-10% if delayed.

Geographic Concentration Risk

High concentration in Europe (36% of revenue) makes the company sensitive to European regulatory shifts and economic stability.

Third Party Dependencies

Dependency on innovator companies for CDMO contracts; delays in their clinical trials or commercial launches directly impact Laurus's revenue.

Technology Obsolescence Risk

Risk of new drug classes replacing current APIs. Mitigated by investing in new technologies like ADCs and gene therapy.

Credit & Counterparty Risk

Liquidity is 'Strong' with gross cash accruals of INR 750 Cr in FY25 against repayment obligations of ~INR 320 Cr, indicating high receivables quality.